Camallergy appoints Baxter Phillips III as Chief Executive Officer
Industry leader brings broad strategic and licensing experience in development-and commercial-stage biopharmaceutical companies
CAMBRIDGE, UK and RICHMOND, VA, US 17th October 2018 – Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced the appointment of Baxter Phillips III as Chief Executive Officer, effective immediately. Mr. Phillips has also been appointed to the Company’s Board of Directors. Camallergy co-founder Sherden Timmins continues his executive appointment in the newly created role of Chief Operating Officer while company scientific co-founders Dr. Andrew Clark and Dr. Pamela Ewan continue to serve in their current roles as Chief Scientific Officer and Chief Medical Officer.
“Baxter comes to Camallergy with first-hand knowledge of patient well-being for those who suffer from food allergies. Coupled with a strategic executive’s vision of how to build and deliver on our mission to bring the best treatment for patients to market, we believe he is an exceptional addition to our team at Camallergy as we advance into Phase 3 trials,” stated Dr. Jonathan Milner, PhD, Chairman of the Camallergy Board of Directors and co-founder of Abcam (LON:ABC).
Mr. Phillips has over 20 years of executive experience and a record of success in leading multinational corporate strategy efforts in the biotechnology and pharmaceutical industry. Most recently, Mr. Phillips was President and CEO of Neurogastrx, where he successfully led the company to its transformational $45 million Series A financing.
Prior to Neurogastrx, Mr. Phillips served as Chief Business Officer of AmpliPhi Biosciences (NYSE:APHB), where he played a pivotal role in establishing the Company’s manufacturing, leading multiple financing campaigns and navigating the company to its NYSE listing. Previously, Mr. Phillips’ leadership appointments included Depomed, where he was responsible for licensing the company's product portfolio of development-stage and marketed products, and Osteologix, where he successfully concluded a global licensing transaction with a multinational pharmaceutical company. Mr. Phillips began his career with Insmed, Inc. where for ten years he held leadership positions in research, licensing, finance, investor relations, and sales and marketing. He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.
Commenting on his appointment Mr. Phillips said: “With life-threatening food allergies in my family, specifically peanut allergy, I have spent the last several years evaluating current treatment options as well as the various treatments in development today. I am thrilled and privileged to join this pioneering team at Camallergy who is developing what I believe to be the most therapeutically attractive solution for peanut allergy patients. Importantly, without sacrificing on clinical effectiveness, Drs. Clark and Ewan have developed a proprietary treatment paradigm that offers the fastest treatment currently in development to safely and effectively desensitize patients to peanuts. In the Cambridge Peanut Allergy Clinic and research studies, Pam and Andy have demonstrated exceptional success by safely treating hundreds of patients. We look forward to confirming these results through our planned Phase 3 clinical trials in 2019 to make this therapy available throughout the UK, Europe and here in the United States.”
Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company dedicated to providing innovative, patient centric treatments to address the millions of patients suffering worldwide from food allergies. Camallergy’s lead product, CA002, is a novel oral immunotherapy for the treatment of peanut allergies designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The company’s unique intellectual property and treatment algorithm is based on the clinical work initiated at Cambridge University Hospital System in Cambridge, U.K., by the scientific co-founders of the company, Dr. Andrew Clark and Dr. Pamela Ewan. Camallergy has its headquarters in Cambridge, U.K., with key functions and members of its leadership team located in the United States. For more information, visit www.camallergy.com.
About Cambridge Peanut Allergy Clinic
Cambridge Peanut Allergy Clinic is a private, pediatric clinic run by the Cambridge University Hospitals NHS Foundation Trust and is directed by Drs. Pamela Ewan and Andrew Clark, who are world-renowned specialists in the fields of allergy and immunotherapy. The clinic offers immunotherapy among a range of services. For more information, visit www.peanut.cuh.org.uk.